Skip to main content
$8.20 +0.14 (+1.74%) At close · Jul 28
Market Cap
$76.66M
Shares
9.35M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.20 Open$8.10 Day$7.78–8.46 52W$6.01–17.44 Avg vol 30d93K Short int383K · 4.1% float · 4.3d Short vol60% Last earningsNov 8, 2022 DataJan 2020–Jul 2026 Filing10-Q · May 13

Up next

FQ3-26 quarter ends
~Sep 26, 2026 Est
filed May 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.2 · elevated Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −0%
below
RSI (14) 48
neutral
MACD trend Negative
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −2%
trailing
6-month return +3%
trailing
YTD return −3%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Distributing
3 of 49 funds reported for Jun 30 · net -3.2K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.10% of float · ▼ -24.2% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — 13F breadth
Squeeze score 54
elevated · 0–100
Fundamentals
Strong
EPS growth +21%
Y/Y
Free cash flow $-97.0M
Balance sheet $38.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −63%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Distributing
3 of 49 funds reported for Jun 30 · net -3.2K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.10% of float · ▼ -24.2% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $6 Now $8 · 19% 52-wk high $17
vs 200-day avg -6% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACET
Adicet Bio, Inc.
this stock
$76.66M -2.6% 4.1%
ONC
BeOne Medicines Ltd.
$477.60B +7.3% +22179.2% 971.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +8.2% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +3.7% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
49
% held
68.5%
Reported
3 of 49
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
383.2K
Days to cover
4.3d
Change
-122.4K sh
View
Short Volume
Short vol %
60%
As of
Jul 28, 2026
Short Total
View
Fails to Deliver
FTD shares
21
Value
$180
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
43.3%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-116.8M
EPS diluted
$-16.95
View
Buybacks
Authorized
shares 1.2M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
10
View
Proposed Sales
Value
$514.2K
Shares
78.5K
Filed
Apr 9, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Aug 11, 2026
Last call
Jun 4, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ACET +3.9% -2.0% +2.8% -5.1% -2.6%
SPY -1.0% 0.0% +7.4% -0.8% +8.6%
vs SPY +4.9% -2.0% -4.7% -4.3% -11.3%

Capital returns

Buyback program · as of Feb 28, 2021
Authorized
shares 1.15M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1720580 CUSIP 007002207 13F (30d) 2 filings 2 filers Visit website Investor relations